Anavex Life Sciences Corp (AVXL)

[Doktornolittle]

The significance of the adaptive trial with EEG and biomolecular indicators.

For Anavex 2-73 plus they have two drugs to coordinate in trying to nail down dosage, etc.. That is 4 times more difficult than optimizing for a single drug, not two times. If they had to wait six months to get feedback on the efficacy of a given dosing combination, then it would take a very long time to cover a wide range of possibilities. If they don't cover a wide range, they could miss the optimum (they might optimize to a local optimum that is not the global optimum). These tools for quickly detecting efficacy make it possible for them to move very quickly toward an optimum combination for Anavex 2-73 plus. They also help to move faster for evaluating Anavex 2-73 itself.

I don't think the tools even have to work super well for them to assist in this effort. They just have to work fairly well.

They probably have a pretty good idea of the needed dosing, but it is smart to cast a wide net in the effort to catch the optimum before launching a phase 3. I don't see enough of this kind of thing going on. This rings true and it rings smart.

At least that is how I recently started to see it.